What is the optimal management plan for a 205‑lb lawyer with chronic sleep‑maintenance insomnia (3–4 years), mild obstructive sleep apnea previously treated with a mandibular advancement device (not advanced), recent worsening after vertebral disc surgery and biceps tendon repair, recent panic attacks, anxiety, minimal daytime sleepiness (Epworth 1), currently on magnesium and trazodone 50 mg without benefit, and who has tried CBT‑I, sleep restriction, and journaling?

Discontinue trazodone and initiate suvorexant or doxepin for sleep-maintenance insomnia

You should stop the trazodone 50 mg immediately, as the American Academy of Sleep Medicine explicitly recommends against using trazodone for sleep-maintenance insomnia 1. Despite being FDA-approved for depression, trazodone lacks evidence for insomnia efficacy and your patient has already demonstrated no benefit after several weeks of use 2.

Immediate Pharmacologic Management

For this patient's sleep-maintenance insomnia (waking at 2-3 AM unable to return to sleep), the 2017 AASM guideline provides clear first-line options 1:

Recommended Medications (in order of preference):

1. Suvorexant 10-20 mg – Orexin receptor antagonist specifically indicated for sleep maintenance; start 10 mg and titrate based on response 1

2. Doxepin 3-6 mg – Low-dose heterocyclic antidepressant with specific evidence for sleep maintenance 1

3. Eszopiclone 2-3 mg – Benzodiazepine receptor agonist effective for both sleep onset and maintenance 1

4. Temazepam 15 mg – Intermediate-acting benzodiazepine for sleep onset and maintenance 1

Given the recent panic attacks and anxiety, I would prioritize suvorexant or low-dose doxepin over benzodiazepine receptor agonists, as the latter may complicate anxiety management and carry higher dependence risk in this already-distressed patient.

Critical Comorbidity: Address the Mild OSA

The mandibular advancement device (MAD) was never advanced after fabrication—this is a critical oversight. The patient reports initial benefit with snoring resolution, suggesting the device has potential efficacy but requires titration 3, 4.

OSA Management Steps:

• Refer back to the dentist/sleep medicine specialist to advance the MAD incrementally until optimal therapeutic position is achieved 3, 5

• The recent worsening since the surgeries may reflect:

  • Weight changes affecting OSA severity
  • Positional changes during recovery
  • Inadequate MAD adjustment
  • Pain/anxiety disrupting sleep architecture

• Consider repeat sleep study with MAD in situ to document current apnea-hypopnea index and guide further MAD adjustment 4, 6

The mild OSA itself can perpetuate sleep-maintenance insomnia through nocturnal arousals, even without conscious awareness of apneic events 7, 8. Optimizing OSA treatment may independently improve the insomnia.

Address the Anxiety and Recent Decompensation

The patient's recent panic attacks and worsening anxiety surrounding sleep represent conditioned arousal and anticipatory anxiety—a hallmark of chronic insomnia that perpetuates the disorder 9.

Psychiatric Coordination:

• Ensure psychiatry is addressing the panic disorder and anxiety with appropriate anxiolytic management (SSRIs, SNRIs, or buspirone—not benzodiazepines given the OSA) 9

• The anxiety may be:

  • Primary (requiring independent treatment)
  • Secondary to chronic sleep deprivation
  • Exacerbated by recent surgical stressors and pain

• The insomnia and anxiety are likely bidirectionally reinforcing—treating one without the other will yield suboptimal results 9

Reinforce and Intensify CBT-I

Although the patient has "completed" CBT-I, the recent decompensation suggests need for booster sessions or intensified behavioral intervention 9, 10:

• Stimulus control therapy – Strict bed/bedroom association with sleep only; get out of bed if awake >15-20 minutes 9, 10
• Sleep restriction therapy – Currently getting 2-3 hours some nights suggests the sleep window may need temporary restriction to consolidate sleep drive (e.g., restrict time in bed to 5.5-6 hours initially, then expand as sleep efficiency improves) 9, 10
• Cognitive therapy – Address catastrophic thinking about sleep consequences, performance anxiety, and hyperarousal 9, 10

The 2008 and 2021 AASM guidelines emphasize that CBT-I should be combined with pharmacotherapy when possible, not replaced by it 9, 10. The patient's current crisis warrants combined treatment.

Monitoring and Follow-Up

Per AASM consensus recommendations 9:

• Reassess every 2-4 weeks initially until insomnia stabilizes
• Sleep diary throughout treatment to track wake after sleep onset, total sleep time, sleep efficiency
• Epworth Sleepiness Scale (currently 1/24—remarkably low despite severe insomnia, suggesting hyperarousal rather than sleepiness)
• Re-evaluate every 6 months long-term, as insomnia relapse rates are high 9

Specific Monitoring for Pharmacotherapy:

• Suvorexant: Monitor for next-day somnolence (though unlikely given current hyperarousal), complex sleep behaviors, suicidal ideation (black box warning for all sleep medications) 1
• Doxepin: Monitor for anticholinergic effects (dry mouth, constipation, urinary retention), though minimal at 3-6 mg doses 1

What NOT to Do

Avoid these common pitfalls:

• Do not continue trazodone—it has a negative recommendation for insomnia 1
• Do not use diphenhydramine (Unisom), melatonin, or valerian—all have negative recommendations from AASM 1
• Do not prescribe benzodiazepines long-term given the OSA and risk of respiratory depression 7
• Do not ignore the MAD optimization—untreated OSA will perpetuate insomnia regardless of hypnotic choice 7, 8, 3
• Do not treat insomnia in isolation—the panic attacks and anxiety require concurrent psychiatric management 9

Weight and Lifestyle

At 205 lbs, assess BMI and consider weight loss if overweight/obese, as this is the single most modifiable risk factor for OSA severity 7. Even 10% weight reduction can significantly improve OSA and may reduce insomnia severity 7.

• Maintain single cup of coffee daily (current intake is appropriate)
• Continue avoiding alcohol (correct decision given OSA)
• Optimize sleep hygiene as adjunct (though insufficient alone) 9, 10

Summary Algorithm

1. Stop trazodone immediately 1
2. Start suvorexant 10 mg or doxepin 3 mg for sleep-maintenance insomnia 1
3. Refer for MAD advancement and possible repeat sleep study 3, 4, 5
4. Coordinate with psychiatry for panic/anxiety management 9
5. Reinitiate/intensify CBT-I with focus on stimulus control and sleep restriction 9, 10
6. Reassess in 2-4 weeks, then every 6 months long-term 9

This patient's insomnia is multifactorial (chronic primary insomnia, comorbid anxiety/panic, undertreated OSA, recent surgical stressors) and requires simultaneous optimization of all contributing factors to restore quality of life and work performance.